BRIEF—Sage launches first therapy for postpartum depression

Sage Therapeutics has launched Zulresso (brexanolone), following its approval in the USA in March 2019.

Zulresso, the first and only treatment specifically approved for postpartum depression, is administered via continuous intravenous infusion for 2.5 days, under the supervision of an authorized healthcare provider.

It is the 11th FDA-approved drug to use Ligand Pharmaceutial’s Captisol technology, which is designed to improve the solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).